See more : OPKO Health, Inc. (0KCS.L) Income Statement Analysis – Financial Results
Complete financial analysis of HLB Co., Ltd. (028300.KQ) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of HLB Co., Ltd., a leading company in the Biotechnology industry within the Healthcare sector.
- Discovery Minerals Ltd. (DSCR) Income Statement Analysis – Financial Results
- E-Star Commercial Management Company Limited (6668.HK) Income Statement Analysis – Financial Results
- Ozon Holdings PLC (OZON.ME) Income Statement Analysis – Financial Results
- Hypertension Diagnostics, Inc. (HDII) Income Statement Analysis – Financial Results
- UGRO Capital Limited (UGROCAP.NS) Income Statement Analysis – Financial Results
HLB Co., Ltd. (028300.KQ)
About HLB Co., Ltd.
HLB Co., Ltd. manufactures pharmaceutical products, and builds ships. It manufactures and sells various types of lifeboats for marine plants, drill ships, and cruise vessels in South Korea. The company offers conventional type lifeboats, free fall type lifeboats, and rescue boats. It also provides marine and yacht engines; hooks; RIB, patrol, fishing, aluminum, and leisure boats; fishery inspection ships; and safety goods, as well as lifeboat and davit inspection and repair services, service engineering training, and spare parts for lifeboats and davits. In addition, the company develops Riboseranib, a targeted anti-cancer agent; and Apilia that is used for the treatment for ovarian cancer. HLB Co., Ltd. was founded in 1975 and is headquartered in Ulsan, South Korea.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 42.90B | 179.71B | 69.83B | 56.18B | 38.42B | 36.19B | 23.01B | 30.14B | 38.46B | 37.19B | 20.81B | 51.64B |
| Cost of Revenue | 43.99B | 128.45B | 59.57B | 55.20B | 35.47B | 29.95B | 21.18B | 26.10B | 32.77B | 31.27B | 18.34B | 44.68B |
| Gross Profit | -1.09B | 51.26B | 10.26B | 978.83M | 2.95B | 6.23B | 1.83B | 4.04B | 5.69B | 5.92B | 2.47B | 6.96B |
| Gross Profit Ratio | -2.53% | 28.52% | 14.69% | 1.74% | 7.68% | 17.22% | 7.95% | 13.41% | 14.78% | 15.92% | 11.87% | 13.47% |
| Research & Development | 49.15B | 43.87B | 48.42B | 22.59B | 33.83B | 22.23B | 12.67B | 10.09B | 2.03B | 653.73M | 1.27B | 1.82B |
| General & Administrative | 7.33B | 6.89B | 4.28B | 2.97B | 84.48M | 72.83M | 108.95M | 74.25M | 63.85M | 48.58M | 45.89M | 148.08M |
| Selling & Marketing | 25.67B | 15.84B | 18.53B | 11.97B | 4.93B | 1.59B | 3.20B | 2.17B | 1.60B | 708.55M | 886.66M | 744.26M |
| SG&A | 33.00B | 82.02B | 61.58B | 69.76B | 17.35B | 13.67B | 14.25B | 17.26B | 13.19B | 4.24B | 5.49B | 7.81B |
| Other Expenses | 41.99B | -25.94M | -98.55M | 65.69M | 167.04M | 315.75M | -301.21M | -1.93M | -171.52M | 0.00 | 0.00 | 0.00 |
| Operating Expenses | 124.13B | 125.92B | 110.09B | 92.29B | 51.02B | 35.58B | 27.22B | 27.35B | 15.39B | 6.14B | 10.92B | 11.75B |
| Cost & Expenses | 167.93B | 254.37B | 169.66B | 147.49B | 86.49B | 65.53B | 48.40B | 53.45B | 48.17B | 37.41B | 29.26B | 56.43B |
| Interest Income | 6.73B | 1.61B | 1.28B | 1.68B | 805.99M | 11.88B | 3.60B | 404.15M | 2.29B | 1.58B | 561.83M | 1.71B |
| Interest Expense | 10.59B | 11.69B | 3.63B | 5.26B | 19.51B | 12.77B | 4.23B | 930.02M | 2.84B | 1.94B | 978.65M | 1.92B |
| Depreciation & Amortization | 9.68B | 16.33B | 12.03B | 10.44B | 2.13B | 1.32B | 1.58B | 1.55B | 1.70B | 1.82B | 2.26B | 2.85B |
| EBITDA | -172.28B | -59.43B | -87.80B | -80.82B | -40.01B | 27.59B | -27.33B | -20.72B | 14.83B | 2.46B | -5.94B | -1.95B |
| EBITDA Ratio | -401.58% | -32.46% | -125.75% | -143.96% | -119.58% | -77.45% | -103.50% | -72.18% | -20.80% | 6.62% | -12.66% | -1.78% |
| Operating Income | -125.02B | -74.66B | -99.83B | -91.31B | -48.07B | -29.35B | -25.39B | -23.31B | -9.71B | 636.13M | -4.89B | -3.77B |
| Operating Income Ratio | -291.43% | -41.55% | -142.98% | -162.54% | -125.12% | -81.10% | -110.36% | -77.33% | -25.23% | 1.71% | -23.51% | -7.29% |
| Total Other Income/Expenses | -87.77B | -13.75B | -9.43B | -1.89B | -11.69B | 42.82B | -7.96B | 54.84M | 20.28B | -2.16B | -3.66B | -2.73B |
| Income Before Tax | -212.80B | -79.01B | -102.09B | -82.98B | -61.65B | 13.50B | -33.35B | -22.26B | 10.29B | -1.80B | -9.01B | -6.50B |
| Income Before Tax Ratio | -496.02% | -43.96% | -146.21% | -147.71% | -160.45% | 37.31% | -144.97% | -73.87% | 26.75% | -4.84% | -43.31% | -12.59% |
| Income Tax Expense | -6.75B | 10.19B | 1.16B | -4.49B | -103.24M | -17.51M | -12.02B | -10.04B | -2.19B | -316.99M | -2.23B | 782.00K |
| Net Income | -189.08B | -78.16B | -98.13B | -80.09B | -44.39B | 25.34B | -16.53B | -13.21B | 12.64B | -1.48B | -6.78B | -5.25B |
| Net Income Ratio | -440.74% | -43.49% | -140.53% | -142.57% | -115.53% | 70.04% | -71.85% | -43.85% | 32.86% | -3.98% | -32.58% | -10.17% |
| EPS | -1.56K | -694.20 | -816.50 | -647.59 | -438.25 | 265.34 | -180.85 | -145.93 | 150.41 | -23.71 | -116.58 | -109.13 |
| EPS Diluted | -1.56K | -694.20 | -816.50 | -647.59 | -438.25 | 265.34 | -180.85 | -145.93 | 147.70 | -23.71 | -116.58 | -109.13 |
| Weighted Avg Shares Out | 121.24M | 112.59M | 120.18M | 123.68M | 101.28M | 95.51M | 91.40M | 90.55M | 84.04M | 62.48M | 58.16M | 48.11M |
| Weighted Avg Shares Out (Dil) | 121.24M | 112.59M | 120.18M | 123.68M | 101.28M | 95.51M | 91.40M | 90.55M | 85.58M | 62.48M | 58.16M | 48.11M |
Source: https://incomestatements.info
Category: Stock Reports